Researchers have focused on changes in the gut bacteria to figure out who is at risk for a loss of beta cell function.
Advances in type 1 diabetes (T1D) aren’t just in treatment and better management tools—scientists have also been looking for ways to prevent the disease.
While it is known that T1D is an autoimmune disease with both genetic and environmental triggers, researchers have been looking for a biomarker—a biological signal that would tip off who was at risk of beta cell destruction in the pancreas, which leaves the body unable to produce its own insulin.
Researchers in France, at CNRS (Centre Nationnal de la Recherche Scientifique) and Paris University, have discovered that just before the onset of T1D, the body experiences changes in cells known as MAIT lymphocytes (mucosal associated invariant T cells). MAIT cells are part of the immune system and are activated by gut microbiota, and the French researchers examined the connection between the MAIT cells and the disturbances of gut flora as they relate to T1D.
The results were published Monday in the journal Nature Immunology.
The investigations included an examination of both animal models, led by Agnes Lehuen, as well studies of blood samples taken from patients in Necker-Enfants Malades Hospital. Both showed changes in the MAIT cells just before T1D develops.
When T1D is diagnosed in children, they had fewer MAIT cells in their blood than found in children without diabetes. The study teams observed that pancreatic MAIT cells swelled in diabetic mice who were not obese, suggesting that when the missing MAIT cells in the diagnosed children had migrated to the inflamed pancreatic tissue.
According to a statement from the study team, “Experiments performed by the researchers on human cells in vitro and on (nonobese diabetic) mice suggest MAIT cells are directly linked to the destruction of pancreatic beta cells.”
The studies uncovered 2 qualities about the function of the MAIT cells in patients who develop T1D that may suggest their future value as a biomarker:
Reference
Rouxel O, Da silva J, Beaudoin L, et al. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes [published October 9. 2017]. Nat Immunol. doi:1 0.1038/ni.3854.
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More